SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ICOS Corporation -- Ignore unavailable to you. Want to Upgrade?


To: DGMontana who wrote (678)5/11/1999 10:55:00 AM
From: opalapril  Read Replies (4) | Respond to of 1139
 
Here is my (uninformed) take. Of all the small, start-up biotechs ICOS has the best management. Cash in coffers is ample. Pipeline is broad, significant, and promising. Mutual fund interest is high. Within the industry there are few if any better investments. Although the current stock price may look high to you, if things pan out and it follows to any degree the past history of AMGN, in a few years you won't even notice the difference between $20 and $42.

There is always a possibility the entire market or industry will collapse, but it seems to me the chance of a market collapse in the foreseeable future is small and biotechs as a group already are pretty well been beaten down.

In a word, ICOS is one biotech investment that lets you sleep.



To: DGMontana who wrote (678)5/12/1999 1:06:00 AM
From: synchro  Read Replies (2) | Respond to of 1139
 
Immunex (which I've held for 4 yrs and continue to hold) might provide some clue as to how biotech stock behaves as it progresses thru the various stages of clinical trials. Back in November last, if you have bought after FDA approved Enbrel, the stock quadrupled from there--definitely not chump change. It just goes to show that there are plenty of upside during each successful milestone. Has ICOS gone thru any milestone recently? If not, then the recent surge is just sectoral 'surge-in-sympathy'; I wouldn't add at this stage.
My 2c